<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097395</url>
  </required_header>
  <id_info>
    <org_study_id>08-1198</org_study_id>
    <secondary_id>K23DK082621</secondary_id>
    <nct_id>NCT01097395</nct_id>
  </id_info>
  <brief_title>Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection</brief_title>
  <official_title>Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if concentration-controlled ribavirin dosing can&#xD;
      achieve a targeted level of plasma exposures and if it appears safe and effective compared&#xD;
      with standard weight-based ribavirin dosing. Forty, previously treatment-naive participants&#xD;
      with genotype 1 disease will be randomized to receive concentration-guided or standard&#xD;
      weight-based ribavirin. Peginterferon alfa 2a,ribavirin, and telaprevir will be provided&#xD;
      through the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ribavirin AUC-12 Variability</measure>
    <time_frame>steady state (~weeks 9-10)</time_frame>
    <description>Demonstrate that concentration-controlled ribavirin dosing can achieve a targeted level of plasma exposure with reduced variability in the steady-state area-under-the-concentration-time curve (AUC0-12) compared with standard weight-based ribavirin dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Absolute Hemoglobin Declines</measure>
    <time_frame>from baseline through end of treatment, up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Virologic Response (i.e., Cure)</measure>
    <time_frame>assessed 12 weeks after stopping treatment</time_frame>
    <description>Compare proportions with SVR in standard weight-based vs. concentration-guided ribavirin dosing groups. Number of participants with sustained virologic response is reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Standard Weight-Based Ribavirin Dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 mg daily in patients weighing &lt;75 kg and 1200 mg daily in patients weighing ≥ 75 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentration-Controlled Ribavirin Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose adjusted based on first dose AUC0-12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12</description>
    <arm_group_label>Concentration-Controlled Ribavirin Dosing</arm_group_label>
    <arm_group_label>Standard Weight-Based Ribavirin Dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic HCV-infected men and women&#xD;
&#xD;
          -  18-70 years&#xD;
&#xD;
          -  HCV genotype 1&#xD;
&#xD;
          -  Deemed ready for HCV treatment by hepatology provider and patient&#xD;
&#xD;
          -  Allowed medications: all those not specifically listed in the exclusion criteria below&#xD;
             including medications for peginterferon / ribavirin - related adverse effects:&#xD;
             acetaminophen, ibuprofen, diphenhydramine, selective serotonin reuptake inhibitors,&#xD;
             darbepoeitin, erythropoietin, GCSF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous treatment with interferon, peginterferon, investigational HCV drugs,&#xD;
             boceprevir, or ribavirin;&#xD;
&#xD;
          -  baseline absolute neutrophil count (ANC) &lt; 1000/mm3,&#xD;
&#xD;
          -  platelets &lt; 100,000/mm3,&#xD;
&#xD;
          -  hemoglobin &lt; 12 g/dL for women and &lt; 13 g/dL for men;&#xD;
&#xD;
          -  HIV positive serostatus;&#xD;
&#xD;
          -  HBV positive serostatus;&#xD;
&#xD;
          -  decompensated liver disease (i.e., ascites, history of esophageal variceal bleeding,&#xD;
             hepatic encephalopathy);&#xD;
&#xD;
          -  autoimmune hepatitis&#xD;
&#xD;
          -  hemoglobinopathy (e.g., sickle cell anemia, thalassemia)&#xD;
&#xD;
          -  Cockcroft and Gault estimated creatinine clearance &lt; 50 mL/min;&#xD;
&#xD;
          -  alcohol or illicit drug use that in the opinion of the investigator would interfere&#xD;
             with study participation and/or impact study results&#xD;
&#xD;
          -  for females, active pregnancy or any intent to become pregnant during study period or&#xD;
             for up to 6 months after completing treatment&#xD;
&#xD;
          -  for males, a pregnant female partner or intent to impregnate a female during study&#xD;
             period or for up to 6 months after completing treatment&#xD;
&#xD;
          -  for both sexes an unwillingness to use two forms of contraception during the study&#xD;
             period and for 6 months after completing treatment. While on telaprevir and for 2&#xD;
             weeks following discontinuation of telaprevir, females must use two non-hormonal forms&#xD;
             of contraception;&#xD;
&#xD;
          -  history of significant or unstable cardiac disease including severe coronary artery&#xD;
             disease (unstable angina, recent myocardial infarction, chest pain with exertion) or&#xD;
             congestive heart failure;&#xD;
&#xD;
          -  receipt of an organ transplant;&#xD;
&#xD;
          -  malignant neoplastic disease;&#xD;
&#xD;
          -  chronic pulmonary disease that in the opinion of the study hepatologists would&#xD;
             preclude treatment with peginterferon and ribavirin (e.g., pulmonary function tests&#xD;
             ≤70% within the previous 2 years);&#xD;
&#xD;
          -  history of admission to a psychiatric facility within the previous year;&#xD;
&#xD;
          -  suicide attempt within the previous 3 years;&#xD;
&#xD;
          -  concomitant medications including: amantadine, mycophenolate mofetil, and&#xD;
             investigational HCV compounds, alfuzosin, alfentanil, ergot derivatives&#xD;
             (dihydroergotamine/ergotamine/ergonovine/methylergonovine), meperidine,&#xD;
             anti-arrhythmics (quinidine, flecainide, propafenone, amiodarone, bepridil),&#xD;
             astemizole, terfenadine, buspirone, diazepam, estazolam, oral midazolam, triazolam,&#xD;
             budesonide, domperidone, eletriptan, eplerenone, fluticasone, pimozide, salmeterol,&#xD;
             calcium channel blockers (diltiazem, felodipine, nifedipine, nisoldipine, verapamil),&#xD;
             cisapride, cyclosporine, sirolimus, systemic tacrolimus, atorvastatin, lovastatin,&#xD;
             simvistatin, sildenafil, tadalafil, verdenafil, antibiotics (clarithromycin,&#xD;
             erythromycin, telithromycin, troleandomycin), carbamazepine, Phenobarbital, phenytoin,&#xD;
             nefazodone, St. Johns Wort, antifungals (fluconazole, itraconazole, ketoconazole,&#xD;
             posaconazole, voriconazole), rifampin, rifabutin, aprepitant, cholestyramine,&#xD;
             fluvoxamine, mifepreistone, modafinil, systemic dexamethasone. With the exception of&#xD;
             St. Johns Wort, investigators may use their discretion on use of herbal and dietary&#xD;
             supplements.&#xD;
&#xD;
          -  Evidence of severe retinopathy or clinically relevant ophthalmologic disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer J Kiser, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 30, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2010</study_first_posted>
  <results_first_submitted>August 20, 2021</results_first_submitted>
  <results_first_submitted_qc>August 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2021</results_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ribavirin</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Hepatitis C virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Weight-Based Ribavirin Dosing</title>
          <description>1000 mg daily in patients weighing &lt;75 kg and 1200 mg daily in patients weighing ≥ 75 kg&#xD;
ribavirin: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12</description>
        </group>
        <group group_id="P2">
          <title>Concentration-Controlled Ribavirin Dosing</title>
          <description>Dose adjusted based on first dose AUC0-12&#xD;
ribavirin: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Weight-Based Ribavirin Dosing</title>
          <description>1000 mg daily in patients weighing &lt;75 kg and 1200 mg daily in patients weighing ≥ 75 kg&#xD;
ribavirin: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12</description>
        </group>
        <group group_id="B2">
          <title>Concentration-Controlled Ribavirin Dosing</title>
          <description>Dose adjusted based on first dose AUC0-12&#xD;
ribavirin: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.1" spread="10.2"/>
                    <measurement group_id="B2" value="53.4" spread="5.9"/>
                    <measurement group_id="B3" value="50.3" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ribavirin AUC-12 Variability</title>
        <description>Demonstrate that concentration-controlled ribavirin dosing can achieve a targeted level of plasma exposure with reduced variability in the steady-state area-under-the-concentration-time curve (AUC0-12) compared with standard weight-based ribavirin dosing</description>
        <time_frame>steady state (~weeks 9-10)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Weight-Based Ribavirin Dosing</title>
            <description>1000 mg daily in patients weighing &lt;75 kg and 1200 mg daily in patients weighing ≥ 75 kg&#xD;
ribavirin: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12</description>
          </group>
          <group group_id="O2">
            <title>Concentration-Controlled Ribavirin Dosing</title>
            <description>Dose adjusted based on first dose AUC0-12&#xD;
ribavirin: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Ribavirin AUC-12 Variability</title>
          <description>Demonstrate that concentration-controlled ribavirin dosing can achieve a targeted level of plasma exposure with reduced variability in the steady-state area-under-the-concentration-time curve (AUC0-12) compared with standard weight-based ribavirin dosing</description>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34425" spread="10046"/>
                    <measurement group_id="O2" value="40903" spread="10953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety - Absolute Hemoglobin Declines</title>
        <time_frame>from baseline through end of treatment, up to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Weight-Based Ribavirin Dosing</title>
            <description>1000 mg daily in patients weighing &lt;75 kg and 1200 mg daily in patients weighing ≥ 75 kg&#xD;
ribavirin: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12</description>
          </group>
          <group group_id="O2">
            <title>Concentration-Controlled Ribavirin Dosing</title>
            <description>Dose adjusted based on first dose AUC0-12&#xD;
ribavirin: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Absolute Hemoglobin Declines</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.9"/>
                    <measurement group_id="O2" value="3.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Virologic Response (i.e., Cure)</title>
        <description>Compare proportions with SVR in standard weight-based vs. concentration-guided ribavirin dosing groups. Number of participants with sustained virologic response is reported.</description>
        <time_frame>assessed 12 weeks after stopping treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Weight-Based Ribavirin Dosing</title>
            <description>1000 mg daily in patients weighing &lt;75 kg and 1200 mg daily in patients weighing ≥ 75 kg&#xD;
ribavirin: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12</description>
          </group>
          <group group_id="O2">
            <title>Concentration-Controlled Ribavirin Dosing</title>
            <description>Dose adjusted based on first dose AUC0-12&#xD;
ribavirin: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response (i.e., Cure)</title>
          <description>Compare proportions with SVR in standard weight-based vs. concentration-guided ribavirin dosing groups. Number of participants with sustained virologic response is reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Weight-Based Ribavirin Dosing</title>
          <description>1000 mg daily in patients weighing &lt;75 kg and 1200 mg daily in patients weighing ≥ 75 kg&#xD;
ribavirin: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12</description>
        </group>
        <group group_id="E2">
          <title>Concentration-Controlled Ribavirin Dosing</title>
          <description>Dose adjusted based on first dose AUC0-12&#xD;
ribavirin: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin &lt; 8.5 g/dL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tooth pain and vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Astrocytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Frozen arms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mood alteration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin &lt; 10 g/dL</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>ANC &lt; 1000/mm3</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Platelets &lt; 75,000/mm3</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>WBC &lt;2000/mm3</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Grade 3 Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Grade 3 Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Grade 3 Mood Alteration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Shortness of Breath</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Kiser</name_or_title>
      <organization>University of Colorado</organization>
      <phone>3037246131</phone>
      <email>jennifer.kiser@cuanschutz.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

